Bronchitis

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
Sunday, April 7, 2024
Uric acid, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, Atherosclerosis, FAHA, Cleveland Clinic, Bempedoic acid, Ezetimibe, Therapy, Anemia, Pain, MACE, Sinusitis, ACC, FOMA, FNLA, FACC, Obesity, Cardiovascular disease, Esperion Therapeutics, Abdominal pain, Risk, Gout, Spasm, Woman, American College, Body mass index, ESPR, Back pain, Outcome, ATP, Safety, Fatigue, Arthralgia, ANN, Angioedema, Kidney, Journal, Constipation, University, Adverse event, Pregnancy, CLEAR, Rash, MPH, Rupture, FDA, Molina Healthcare, JACC, Hypersensitivity, Health, Circulatory system, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Dietary supplement

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

New Campaign Highlights How Certain Jobs Can Increase a Person's Risk for Lung Disease

Retrieved on: 
Tuesday, April 9, 2024
Pneumonia, Emphysema, Bronchitis, Disease, Tobacco, Agriculture, Risk, Urinary tract infection, Spirometry, Fatigue, Smoke, Quality of life, Sputum, Dust, Mucus, Smoking, Wheeze, American Lung Association, COPD, Air pollution, Workplace, Phlegm, Ageing, Mining, Nursing

CHICAGO, April 9, 2024 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) impacts 11.7 million people living in the U.S. While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD. To help people identify workplace risk factors and encourage them to speak with their healthcare provider if they are experiencing symptoms, the American Lung Association is launching a campaign to raise awareness for occupational COPD. 

Key Points: 
  • While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD.
  • COPD, which includes chronic bronchitis and emphysema, is a long-term lung disease that makes it hard to breathe.
  • Many workplaces may expose workers to risk factors for COPD, but the leading job types that increase risk for chronic lung disease include agriculture, mining and manufacturing.
  • Early treatment of a chronic lung disease, including reducing the exposure, can help lead to better health outcomes.

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Retrieved on: 
Friday, March 22, 2024
Glucose, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, European Medicines Agency, Ezetimibe, Therapy, Anemia, Pain, Sinusitis, Esperion Therapeutics, Bempedoic acid, Abdominal pain, Risk, Gout, Committee, Spasm, ESPR, Back pain, ATP, Safety, Membrane protein, Fatigue, CHMP, Arthralgia, Angioedema, Cardiovascular disease, Kidney, Constipation, Death, Adverse event, Pregnancy, CLEAR, Rash, Esperies, Rupture, FDA, Molina Healthcare, Hypersensitivity, Health, Conference, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Uric acid, Pharmaceutical industry

In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.

Key Points: 
  • In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.
  • They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
  • NEXLETOL and NEXLIZET are also the first oral non-statin LDL-C lowering drugs to be approved by the FDA to reduce the risk of CV events in both primary and secondary prevention patients.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

Retrieved on: 
Friday, March 22, 2024
Urinary tract infection, Anaphylaxis, Bronchitis, European Commission, Tendon rupture, Patient, European Medicines Agency, Bempedoic acid, Ezetimibe, Therapy, Citrate synthase, Anemia, Pain, Sinusitis, Abdominal pain, Risk, Gout, Ageing, Committee, ACL, Spasm, EMA, Back pain, ATP, Safety, Fatigue, CHMP, Arthralgia, Angioedema, Tablet, Constipation, Agent handling, Death, Pregnancy, CLEAR, Rash, Kidney, Moyamoya disease, Rupture, Apolipoprotein, Hypercholesterolemia, Hypersensitivity, Health, CVD, Incidence, Diarrhea, Fetus, Esperion Therapeutics, Diet, Upper respiratory tract infection, FDC, Uric acid

ANN ARBOR, Mich. and MUNICH, Germany, March 22, 2024 (GLOBE NEWSWIRE) -- Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) and Esperion Therapeutics, Inc. jointly announced today, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions for the label update of both bempedoic acid (marketed as NILEMDO®▼) and the bempedoic acid / ezetimibe fixed dose combination (FDC) (marketed as NUSTENDI®▼ ), recommending their approval as treatments to reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk.2 The existing label of bempedoic acid (NILEMDO®▼) provides authorisation for adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:2

Key Points: 
  • “We are thrilled with the positive CHMP opinion, which reflects the significant cardiovascular risk reduction benefit that the bempedoic acid global franchise brings to patients worldwide,” said Sheldon Koenig, President and CEO, Esperion.
  • The CHMP is a scientific committee of the EMA that reviews medical product applications on their scientific and clinical merit.
  • Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels which may lead to gout.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, LYRA, Common, Bronchitis, Disease, MF, New Drug Application, COVID-19, Patient, Smell, Network congestion, CRS, United, Nasal cavity, Pharmacotherapy, Investment, Clinical trial, Therapy, Safety, Sinusitis, ESS, FDA, Food, Pharmaceutical industry

WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.  

Key Points: 
  • WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
  • LYR-220, a larger insert, is designed for CRS patients whose nasal cavity is enlarged due to previous ESS.
  • Cash, cash equivalents and short-term investments were $102.8 million as of December 31, 2023, compared to $102.6 million as of September 30, 2023.
  • The Company recorded an impairment charge of $1.6 million related to long-lived assets for the year ended December 31, 2023.

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Retrieved on: 
Friday, March 22, 2024
FDA, Health, Other Health, Pharmaceutical, Cardiology, Biotechnology, Photograph, Glucose, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, European Medicines Agency, Ezetimibe, Therapy, Anemia, Pain, Sinusitis, Esperion Therapeutics, Bempedoic acid, Abdominal pain, Risk, Gout, Webcast, Committee, Spasm, Splenic infarction, ESPR, Back pain, ATP, Safety, Membrane protein, Fatigue, CHMP, Arthralgia, Angioedema, U.S. FDA, Cardiovascular disease, Kidney, Constipation, Death, Adverse event, Pregnancy, CLEAR, Rash, Rupture, Molina Healthcare, Hypersensitivity, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Multimedia, Uric acid, Dietary supplement

In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.

Key Points: 
  • In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins.
  • They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
  • View the full release here: https://www.businesswire.com/news/home/20240322544788/en/
    U.S. FDA approves broad new labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Open waste burning linked to air pollution in Northwestern Greenland

Retrieved on: 
Tuesday, April 2, 2024
Death, Health, Bronchitis, SDG, Associate, Environmental science, Public, Sustainable Development Goals, Research, University, Smoke, NOAA, Hokkaido University, HYSPLIT, Nagoya University, Particulates, Asthma, Dust, NASA, Atmospheric Science Letters, Air pollution, Coal

SAPPORO, Japan, April 2, 2024 /PRNewswire/ -- To better understand the air quality risks faced by remote Arctic communities, an international team monitored aerial pollutants at a community in Northwestern Greenland. Their findings, published in Atmospheric Science Letters, reveal that open waste burning elevates the concern of health risks to the community.

Key Points: 
  • A case study on the effects of open waste burning on air quality in Northwestern Greenland by Hokkaido University researchers calls attention to the importance of no-one-left-behind sustainable air quality monitoring in the Arctic region.
  • Their findings, published in Atmospheric Science Letters, reveal that open waste burning elevates the concern of health risks to the community.
  • The study focused on Qaanaaq, a small village in Northwestern Greenland with a population of approximately 600.
  • We found out how much pollution increases with PM2.5 during local open waste burning," Yasunari said.

Open waste burning linked to air pollution in Northwestern Greenland

Retrieved on: 
Tuesday, April 2, 2024
Death, Health, Bronchitis, SDG, Associate, Environmental science, Public, Sustainable Development Goals, Research, University, Smoke, NOAA, Hokkaido University, HYSPLIT, Nagoya University, Particulates, Asthma, Dust, NASA, Atmospheric Science Letters, Air pollution, Coal

 SAPPORO, Japan, April 2, 2024 /PRNewswire/ -- To better understand the air quality risks faced by remote Arctic communities, an international team monitored aerial pollutants at a community in Northwestern Greenland. Their findings, published in Atmospheric Science Letters, reveal that open waste burning elevates the concern of health risks to the community.

Key Points: 
  • A case study on the effects of open waste burning on air quality in Northwestern Greenland by Hokkaido University researchers calls attention to the importance of no-one-left-behind sustainable air quality monitoring in the Arctic region.
  • Their findings, published in Atmospheric Science Letters, reveal that open waste burning elevates the concern of health risks to the community.
  • The study focused on Qaanaaq, a small village in Northwestern Greenland with a population of approximately 600.
  • We found out how much pollution increases with PM2.5 during local open waste burning," Yasunari said.

Wyeth launches China's first infant formula with two types of HMOs, leading the way in HMO innovation

Retrieved on: 
Monday, March 25, 2024
Trial of the century, Urinary tract infection, Health maintenance organization, Hospital, Research, HMO, Bronchitis, Xinhua Hospital, Infant

It diminishes lower respiratory tract infections by 55%, bronchitis by 70%, and the likelihood of using antibiotics by 53%.

Key Points: 
  • It diminishes lower respiratory tract infections by 55%, bronchitis by 70%, and the likelihood of using antibiotics by 53%.
  • Meanwhile, based on this ground-breaking innovation, the domestic HMO clinical study project for Chinese infants has officially started.
  • Ms. Shiela Qiu, Regional Business Head, Wyeth Nutrition Greater China Region, stated, "We are thrilled to achieve another milestone in the Chinese infant nutrition market.
  • Wyeth Nutrition is dedicated to fostering the superior growth of the Chinese infant nutrition market, bringing together worldwide research resources and quickening local innovation, and offering Chinese newborns more complete early-life nutrition options."

Wyeth launches China's first infant formula with two types of HMOs, leading the way in HMO innovation

Retrieved on: 
Monday, March 25, 2024
HMO, Xinhua Hospital, Bronchitis, Health maintenance organization, Hospital, Research, Infant, Trial of the century, Urinary tract infection, Multimedia

This clinically proven product offers substantial advantages for the general well-being of newborns between the ages of 0 and 12 months.

Key Points: 
  • This clinically proven product offers substantial advantages for the general well-being of newborns between the ages of 0 and 12 months.
  • It diminishes lower respiratory tract infections by 55%, bronchitis by 70%, and the likelihood of using antibiotics by 53%.
  • Meanwhile, based on this ground-breaking innovation, the domestic HMO clinical study project for Chinese infants has officially started.
  • Ms. Shiela Qiu, Regional Business Head, Wyeth Nutrition Greater China Region, stated, "We are thrilled to achieve another milestone in the Chinese infant nutrition market.